Sugi Predict

Sugi Predict / Compounds / SCHEMBL196857

SCHEMBL196857

SCHEMBL196857

C[S+]([O-])c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.44
▸ CYP2A6 P11509 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ IDO1 P14902 1/20 0.35
▸ CA1 P00915 5/20 0.34
▸ CA2 P00918 5/20 0.34
▸ CA12 O43570 3/20 0.34
▸ CA3 P07451 3/20 0.34
▸ CA4 P22748 3/20 0.34
▸ CA6 P23280 3/20 0.34
▸ CA5A P35218 3/20 0.34
▸ CA7 P43166 3/20 0.34
▸ CA9 Q16790 3/20 0.34
▸ CA13 Q8N1Q1 3/20 0.34
▸ CA14 Q9ULX7 3/20 0.34
▸ CA5B Q9Y2D0 3/20 0.34
▸ ELANE P08246 2/20 0.33
▸ MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15109075 1.00 LMNA (0.44) LMNACYP2A6ALDH1A1CYP3A4MAPK1
SCHEMBL19079696 1.00 LMNA (0.44) LMNACYP2A6ALDH1A1CYP3A4MAPK1
SCHEMBL8779728 0.85 — —
SCHEMBL9635796 0.77 LMNA (0.50) LMNACYP2A6ALDH1A1CYP3A4MAPK1
Disulfoxidie Bis(3,3 Chloro Benzene) SCHEMBL22335884 0.77 LMNA (0.50) LMNACYP2A6ALDH1A1CYP3A4MAPK1
SCHEMBL548628 0.77 LMNA (0.50) LMNACYP2A6ALDH1A1CYP3A4MAPK1
SCHEMBL9637022 0.77 LMNA (0.50) LMNACYP2A6ALDH1A1CYP3A4MAPK1
SCHEMBL17907429 0.77 — —
SCHEMBL254471 0.74 ACHE (0.47) LMNAALDH1A1IDO1CA1CA2
SCHEMBL280535 0.74 ACHE (0.47) LMNAALDH1A1IDO1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 — — US claimed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 — — EP claimed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 — — US claimed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 — — WO claimed
CN-119685854-A Catalyst for preparing sulfone, preparation method thereof and application of catalyst in preparing sulfone by electrocatalytic oxidation of sulfoxide 齐鲁工业大学(山东省科学院) 2025-03-25 — — CN disclosed
CN-117757763-A Sulfoxide reductase mutant and application thereof in chiral sulfoxide preparation 遵义医科大学 2024-03-26 — — CN disclosed
CN-117486662-A Method for synthesizing sulfoxide compound by heterogeneous catalysis 成都理工大学 2024-02-02 — — CN disclosed
US-11872206-B2 Purified forms of rofecoxib, methods of manufacture and use Tremeau Pharmaceuticals, Inc. (US) 2024-01-16 — — US disclosed
CN-114657580-B Electrocatalytic diazonium salt methyl sulfoxide method and methyl sulfoxide derivative 武汉纺织大学 2023-08-29 — — CN disclosed
CN-116334654-A Method for preparing sulfoxide derivative by electrochemically promoting removal of guide group from sulfoxide imine 桂林理工大学 2023-06-27 — — CN disclosed
CN-116219450-A Electrochemical synthesis method of sulfoxide or sulfone compound 成都大学 2023-06-06 — — CN disclosed
US-11617735-B2 Purified forms of rofecoxib, methods of manufacture and use Tremeau Pharmaceuticals, Inc. (US) 2023-04-04 — — US disclosed
EP-1149094-A2 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS Basilea Pharmaceutica AG (CH) 2001-10-31 — — EP disclosed
US-20010034419-A1 Radiation transparent molding materials MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) 2001-10-25 — — US disclosed
WO-2000037464-A2 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS BASILEA PHARMACEUTICA AG (CH) 2000-06-29 — — WO disclosed
US-5409893-A Administering with platinum complexes BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) 1995-04-25 — — US disclosed
EP-0471709-B1 RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS BOEHRINGER MANNHEIM ITALIA (IT) 1994-11-30 — — EP disclosed
EP-0471709-A1 RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS. BOEHRINGER MANNHEIM ITALIA (IT) 1992-02-26 — — EP disclosed
WO-1990013553-A1 RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1990-11-15 — — WO disclosed
US-3987191-A (ORGANOSULFINYLMETHYL)TRI-ORGANOTIN ACARICIDAL COMPOSITIONS AND METHODS OF USE THE PROCTER & GAMBLE COMPANY (US) 1976-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872206-B2 Purified forms of rofecoxib, methods of manufacture and use ITGA2B, F13B, F11 LMNA 3792/4885CYP2A6 747/4885ALDH1A1 2666/4885
US-11617735-B2 Purified forms of rofecoxib, methods of manufacture and use ITGA2B, F13B, F11 LMNA 3792/4885CYP2A6 747/4885ALDH1A1 2666/4885
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A LMNA 2921/4885CYP2A6 2364/4885ALDH1A1 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.